Cas:81803-60-3 Ethyl imidazo[1,5-a]pyridine-3-carboxylate manufacturer & supplier

Chemical Name:Ethyl imidazo[1,5-a]pyridine-3-carboxylate

CAS.NO:81803-60-3

Synonyms:Ethyl imidazo[1,5-a]pyridine-3-carboxylate;Imidazo[1,5-a]pyridine-3-carboxylic acid, ethyl ester;ethyl imidazo<1,5-a>pyridine-3-carboxylate

Molecular Formula:C₁₀H₁₀N₂O₂

Molecular Weight:190.199

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.2±0.1 g/cm3

Index of Refraction:1.594

PSA:43.60000

Exact Mass:190.074234

LogP:1.95

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Ethyl imidazo[1,5-a]pyridine-3-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,pyridine-3-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Imidazo[1,5-a]pyridine-3-carboxylic acid, ethyl ester Use and application,ethyl imidazo&lt technical grade,usp/ep/jp grade.

Related News: In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. Ethyl imidazo[1,5-a]pyridine-3-carboxylate manufacturer The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy. Ethyl imidazo[1,5-a]pyridine-3-carboxylate supplier Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). Ethyl imidazo[1,5-a]pyridine-3-carboxylate vendor Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). Ethyl imidazo[1,5-a]pyridine-3-carboxylate factory Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers.